Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J8ZA
|
|||
| Former ID |
DAP000955
|
|||
| Drug Name |
Quinethazone
|
|||
| Synonyms |
Aquamox; Chinetazone; Chinethazone; Chinethazonum; Hydromox; Idrokin; Quinetazona; Quinethazon; Quinethazonum; Chinetazone[DCIT]; CL 36010; Hydromox (TN); Quinetazona [INN-Spanish]; Quinethazone (aquamox); Quinethazonum [INN-Latin]; Quinethazone (JAN/INN); Quinethazone [INN:BAN:JAN]; 2-Ethyl-7-chloro-1,2,3,4-tetrahydro-4-oxochinazolin-6-sulfonamid; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamide; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-sulfamoylquinazoline; 7-Chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone; 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12ClN3O3S
|
|||
| Canonical SMILES |
CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl
|
|||
| InChI |
1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
|
|||
| InChIKey |
AGMMTXLNIQSRCG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 73-49-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9549, 7784537, 7847527, 8153978, 11467078, 11468198, 11486646, 14800035, 29225299, 46507280, 47499748, 48019132, 48169593, 48243604, 48416507, 48424029, 49699269, 49855752, 56413186, 56463176, 57323335, 77472399, 85787548, 92125946, 103565930, 103870598, 103914667, 104311682, 121363617, 124801002, 125823752, 127403478, 134338229, 134972947, 137156434, 144076234, 144203917, 160964622, 170465167, 175611017, 176262168, 178103863, 178126126, 179149414, 223440822, 226642054, 250104410
|
|||
| ChEBI ID |
CHEBI:8717
|
|||
| SuperDrug ATC ID |
C03BA02
|
|||
| SuperDrug CAS ID |
cas=000073494
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase (CA) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7289). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 013264. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.